Robotic Surgery and Minimally Invasive Urologic Oncology (RSMIUO) Fellowship


The Robotic Surgery and Minimally Invasive Urologic Oncology (RSMIUO) Fellowship at the University of Florida (UF) is a comprehensive, yet flexible, multidisciplinary training opportunity that provides fellows the chance to learn from fellowship-trained leaders in both the Endourological Society and Society of Urologic Oncology who have mastery in laparoscopic and robotic surgery as well as focal therapy. In addition, our team has a strong history of excellence with both investigator-initiated, industry-sponsored, and co-operative group clinical trials within the NCI-designated UF Health Cancer Center (UFHCC). 


During the year, trainees will spend time on clinical rotations and will be directly involved in the management of patients with various urologic malignancies and will be exposed to a broad spectrum of minimally invasive surgical procedures including:

  • Prostate
    • High volume prostate surgery center with dedicated teaching team (>150 prostatectomy/year) 
    • Robotic prostatectomy with various approaches: anterior, posterior, Retzius-sparing and Hood technique
    • Robotic salvage prostatectomy experience
    • da Vinci multiport and SP platform
    • Fusion and transperineal biopsy experience (opportunity to learn micro-ultrasound)
    • Mentors: Drs. Benidir, Joseph, Su
  • Focal Therapy
    • High intensity frequency ultrasound (HIFU)
    • Irreversible electroporation (IRE)
    • Transurethral ultrasound ablation (TULSA)
    • Cryoablation
    • Mentor: Dr. Benidir
  • Kidney
    • Robotic and laparoscopic radical nephrectomy, nephroureterectomy, partial nephrectomy, and caval thrombectomy (>300 renal cases/year)
    • Transperitoneal and retroperitoneal approaches (traditional, SARA)
    • da Vinci multiport and SP platform
    • Mentors: Drs. Benidir, Crispen, Joseph, O’Malley, Su
  • Bladder
    • Advanced understanding of urothelial carcinoma
    • Clinical trials: learn the ins and outs of running clinical trials effectively and receive mentorship in designing investigator-initiated trials
    • Robotic radical cystectomy, robotic partial cystectomy (>50 radical cystectomy alone/year)
    • Intracorporeal (and extracorporeal) urinary diversions: conduit, Indiana pouch, neobladder
    • da Vinci multiport and SP platform
    • Transurethral resection of bladder tumors (Blue light)
    • Nephron sparing endoscopic approaches (Thulium)
    • Mentors: Drs. Benidir, Crispen, O’Malley
  • Testis
    • Robotic retroperitoneal lymph node dissection 
    • Transperitoneal, da Vinci multiport
    • Mentor: Dr. O’Malley

Application to the Program

If you are interested in applying for the Fellowship Program, please visit the Endourological Society’s website  Endourology Society UF Fellowship Application to download and complete the application. After completion, you should email a pdf of your application and your curriculum vitae, to: Jennifer.Thompson@urology.ufl.edu


Program Faculty


Tarik Benidir

Tarik Benidir MD

Clinical Assistant Professor
Department: MD-UROLOGY
Physical Address:
1600 SW ARCHER RD
GAINESVILLE FL 32610

My name is Tarik Benidir, MD, and I am a clinical assistant professor at the University of Florida Department of Urology. I received my medical degree from Queens University School of Medicine in Kingston, Ontario, followed by a residency in urology at the University of Toronto and a urologic oncology fellowship at the Cleveland Clinic in Ohio.

As a urologist that specializes in urologic cancer, I provide surgical management to patients with localized or locally advanced prostate cancer. I offer treatment through robotic prostatectomy for the whole gland as well as prostate focal therapy using various modalities. Furthermore, I am trained to utilize robotic cystectomy with intracorporal diversion for bladder cancer management and other robotic procedures for kidney and ureteral cancers.

My research focuses on the optimization of patient selection for prostate focal therapy and the use of genomics, advanced imaging and artificial intelligence to better treat prostate cancer patients.

In addition to my clinical practice, I enjoy educating and mentoring the next generation of urologists.

Subspecialties:
  • Surgical Oncology
  • Urology
Clinical Interests:
  • Bladder Cancer
  • Focal Therapy for Prostate Cancer
  • Focal Therapy: High-Intensity Focused Ultrasound for Prostate Cancer (HIFU)
  • Kidney Cancer
  • Laparoscopic Radical Nephrectomy
  • Laparoscopic and Robotic Nephroureterectomy
  • Laparoscopic and Robotic Partial Nephrectomy
  • Prostate Biopsy
  • Prostate Cancer
  • Transperineal Biopsy for Prostate Cancer
  • UF Health robotic prostatectomy
  • Upper Tract Urothelial Cancer
  • Urologic Cancer
Publications:
Grants:
  • Nov 2024 ACTIVE
    Salvage Focal Therapy via High Intensity Focused Ultrasound (HIFU) in Radiorecurrent Localized Prostate Cancer (FocalHIFU) (NCT06402357)
    EDAP TECHNOMED · Principal Investigator
Education:
  • 2021-2023
    Fellowship, Urologic Oncology
    Cleveland Clinic
  • 2016-2021
    Residency, Urology
    University of Toronto
  • 2012-2016
    Medical School
    Queens University School of Medicine
Paul L Crispen

Paul L Crispen M.D.

Clinical Professor, David A. Cofrin Professor of Urology, Associate Director of Clinical Research UFHealth Cancer Center
Department: MD-UROLOGY
Mailing Address:
PO Box 100247
GAINESVILLE FL 32610
Physical Address:
1600 SW ARCHER RD
GAINESVILLE FL 32610

As a urologic oncologist, I specialize in the surgical treatment of urothelial carcinoma of the bladder, kidney and ureters. My training as a Urologic Oncologist began at Temple University School Medicine where I received my medical degree and completed a Urology residency. Following completion of residency I received fellowship training in Urologic Oncology at the Mayo Clinic.

My clinical interests focus on the surgical management of bladder cancer, including radical cystectomy and minimally invasive techniques such as laparoscopic robotic cystectomy. While my practice focuses on the surgical management of urologic malignancies I place great emphasis on multidisciplinary cancer care involving medical and radiation oncologists.

My research interest is primarily related to improving the evaluation and treatment of patients presenting with genitourinary malignancies. To date, most of my research effort has focused on the management of bladder and kidney cancer. Additionally, I have a strong interest in involving appropriately selected patients in clinical trials which are designed to evaluate new treatment regimens and hopefully improve the care of patients at the University of Florida and beyond.

Accomplishments:
  • Golden Gator Award
    2018 · UFHealth Cancer Center
  • Gold Humanism Award
    2018 · University of Florida School of Medicine
  • Examplary Teacher Award
    2018 · University of Florida College of Medicine
  • UF Honored Care Giver
    2017 · UFHealth
  • Resident Teaching Award
    2017 · Department of Urology, University of Florida
  • Exemplary Teacher Award
    2017 · University of Florida College of Medicine
  • Physician Recognition Award
    2016 · UFHealth
  • UF Health Cancer Center MVP Award
    2015 · UF Health Cancer Center
  • Shands Patient Service Recognition Award
    2014 · UF Health Shands
  • ASCO Foundation Merit Award, GU ASCO
    2009 · ASCO Foundation
  • Outstanding Poster Presentation
    2005 · Society of Urologic Oncology
Certifications:
  • Urology
    American Board of Urology
Specialties:
  • Cancer
  • Urology
Clinical Interests:
  • Bladder Biopsy
  • Bladder Cancer
  • Cystoscopy
  • Cytology Exam of Urine
  • Kidney Cancer
  • Penile Cancer
  • Renal Cell Carcinoma
  • Renal Pelvis or Ureter Cancer
  • Robotic and Laparoscopic Urologic Surgery
  • Testicular Cancer
  • Upper Tract Urothelial Cancer
  • Urologic Cancer
Publications:
Grants:
  • Jul 2025 ACTIVE
    Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (ASCENT)
    FL DEPT OF HLTH · Co-Investigator
  • Apr 2025 ACTIVE
    A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
    SURGE THERAPEUTICS · Principal Investigator
  • Jan 2025 ACTIVE
    PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]
    NRG ONCOLOGY FOU · Principal Investigator
  • Jan 2025 ACTIVE
    A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)
    Merck Sharp & Dohme · Principal Investigator
  • Nov 2024 ACTIVE
    Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
    DELTA-FLY PHARMA · Principal Investigator
  • Nov 2024 ACTIVE
    Salvage Focal Therapy via High Intensity Focused Ultrasound (HIFU) in Radiorecurrent Localized Prostate Cancer (FocalHIFU) (NCT06402357)
    EDAP TECHNOMED · Faculty
  • Nov 2024 ACTIVE
    Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
    DANA FARBER CANCER INST · Principal Investigator
  • Oct 2024 ACTIVE
    A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
    EXELIXIS · Principal Investigator
  • Sep 2024 ACTIVE
    LLS funding for Improving risk assessment of AML with a precision genomic strategy to assess mutation clearance
    BLOOD CANCER UNITED · Principal Investigator
  • Jul 2024 ACTIVE
    Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
    NRG ONCOLOGY FOU · Principal Investigator
  • Jul 2024 ACTIVE
    Enhancing Connection and Communication with Community-Based Oncology Practices to Improve Cancer Clinical Trial Recruitment: The ECCO Study
    BLOOD CANCER UNITED · Co-Investigator
  • Mar 2024 ACTIVE
    Adstiladrin Early Utilization and Outcomes in the Real World Setting in the United States
    FERRING PHARMACEUTICALS · Principal Investigator
  • Aug 2023 – Aug 2024
    ASCO Screening and Enrollment Qualitative Study
    AMER SOC FOR CLINICAL ONCOLOGY · Principal Investigator
  • Jun 2023 ACTIVE
    UF Health Cancer Center Support Grant
    NATL INST OF HLTH NCI · Other
  • Mar 2022 – Oct 2023
    A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
    JANSSEN RESEARCH AND DEVELOPMENT · Principal Investigator
  • Mar 2022 ACTIVE
    A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
    JANSSEN RESEARCH AND DEVELOPMENT · Principal Investigator
  • Feb 2022 ACTIVE
    Phase 1/2, open-label, multicenter study to evaluate a dosing regimen with two step-up priming doses and longer dosing intervals of Elranatamab (PF-06863135) monotherapy in participants with relapsed/refractory multiple myeloma
    PFIZER INC · Principal Investigator
  • Nov 2021 ACTIVE
    Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
    NRG ONCOLOGY FOU · Principal Investigator
  • Apr 2021 – Jan 2022
    Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG S1806)
    NRG ONCOLOGY FOU · Principal Investigator
  • Aug 2020 ACTIVE
    A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features
    RADIATION THERAPY ONCOLOGY GROUP FOU · Principal Investigator
  • Jul 2020 ACTIVE
    Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2020 – Apr 2020
    NCTN High Performing Site Initiative (HPSI)
    PPD DEVELOPMENT · Principal Investigator
  • Nov 2019 – Jan 2020
    NCTN High Performing Site Initiative (HPSI)
    PPD DEVELOPMENT · Principal Investigator
  • May 2019 ACTIVE
    PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]
    NRG ONCOLOGY FOU · Principal Investigator
  • May 2019 ACTIVE
    A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND # 70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 – Feb 2025
    Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 ACTIVE
    Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Stu
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 ACTIVE
    PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 ACTIVE
    PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 ACTIVE
    PHASE II TRIAL OF INTRAVESICAL GEMCITABINE AND MK-3475 (PEMBROLIZUMAB) IN THE TREATMENT OF PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
    NRG ONCOLOGY FOU · Principal Investigator
  • Mar 2019 ACTIVE
    NRG Affiliate Master-Federal
    NRG ONCOLOGY FOU · Principal Investigator
  • Sep 2018 – Sep 2023
    Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    SWOG CLINICAL TRIALS INITIATIVE · Principal Investigator
  • Jul 2018 ACTIVE
    A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With Multiple Myeloma – The GENESIS Study
    BIOLINE RX · Principal Investigator
  • May 2018 – Mar 2021
    Dissecting the Mechanisms of Tumor-Induced Tolerance and Immune Suppression
    FL DEPT OF HLTH BIOMED RES PGM/J&E KING · Faculty
  • Mar 2018 – Feb 2019
    NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER
    NRG ONCOLOGY FOU · Principal Investigator
  • Jan 2018 ACTIVE
    A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Na?ve High-Grade Non-Muscle Invasive Bladder Cancer
    NRG ONCOLOGY FOU · Principal Investigator
  • Sep 2017 – May 2024
    A Phase III, Open Label Study to Evaluate the Safety and Efficay of INSTILADRIN (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grad, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
    FKD THERAPIES · Principal Investigator
  • Jun 2017 – Oct 2023
    A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY
    SYNEOS HEALTH · Principal Investigator
  • Feb 2017 – Feb 2022
    Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    NRG ONCOLOGY FOU · Principal Investigator
  • Aug 2016 – Dec 2022
    A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
    BRISTOL MYERS SQUIBB CO · Principal Investigator
  • May 2016 – Aug 2022
    A RANDOMIZED DOUBLE BLINDED PHASE II STUDY OF MAINTENANCE PEMBROLIZUMAB VERSUS PLACEBO AFTER FIRST LINE CHEMOTHERAPY..
    HOOSIER CANCER RESEARCH NETWORK · Principal Investigator
  • Jul 2015 – Jul 2020
    AN OPEN LABEL, SINGLE ARM PHASE II MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF CG0070 ONCOLYTIC VECTOR REGIMEN IN
    CG ONCOLOGY · Principal Investigator
  • Jan 2015 – Sep 2021
    A PHASE III RANDOMIZED CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERSUS PACLITAXEL, DOCETAXEL OR VINFLUNINE….
    Merck Sharp & Dohme · Principal Investigator
Patents:
  • Published December 2022
    Materials and Methods for the Diagnosis and Treatment of Cancer
    #US-2023-0341408-A1
Education:
  • 2009
    Fellowship – Urologic Oncology
    Mayo Clinic
  • 2007
    Residency – Urology
    Temple University Hospital
  • 2001
    M.D.
    Temple University School of Medicine
John Michael DiBianco

John Michael DiBianco M.D.

Assistant Professor
Department: MD-UROLOGY
Physical Address:
1600 SW Ar
GAINESVILLE FL 32611

My name is John Michael DiBianco, MD, and I joined the department of urology in 2022. I received my bachelor’s degree in psychology from Trinity College in Hartford, Connecticut and medical degree from Ross University School of Medicine. I completed a general surgery internship and urologic surgery residency at George Washington University School of Medicine & Health Sciences in Washington, D.C. Afterward, I completed a fellowship in endourology at the University of Michigan.

I am now an assistant professor in the department of urology, and my clinical interests include general surgical urology, minimally invasive surgery and specifically the management of kidney stone disease and symptomatic prostate enlargement. My research focus includes quality improvement (QI), the goal of which is to improve the delivery, experience and outcomes of care. I aim to ensure that the choice of treatment is medically appropriate while aligning with the goals of the patient.

In my free time, I enjoy exercising to stay both physically and mentally fit. Additionally, I enjoy movies and experiencing how new movies compare to the classics.

Specialties:
  • Urology
Clinical Interests:
  • Benign Prostate Hyperplasia (enlarged prostate)
  • Kidney Stones
  • Laparoscopic Renal Cyst Ablation
  • Laparoscopic Robotic Pyeloplasty
  • Lithotripsy
  • Percutaneous kidney procedures
  • Robotic and Laparoscopic Urologic Surgery
  • Transperineal Biopsy for Prostate Cancer
  • Ureteroscopy
Publications:
Grants:
  • May 2024 – Nov 2025
    Stent Omission after Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative (SOUL MUSIC)
    UNIV OF MICHIGAN · Principal Investigator
Education:
  • 2020-2022
    Fellowship, Endourology
    University of Michigan
  • 2016-2020
    Residency, Urologic Surgery
    George Washington University
  • 2015-2016
    Internship, General Surgery
    George Washington University
  • 2010-2014
    Medical School
    Ross University
Padraic O'Malley

Padraic O'Malley MSc, MD, FRCSC

Associate Professor
Department: MD-UROLOGY
Mailing Address:
PO Box 100247
GAINESVILLE FL 32610
Physical Address:
PO Box 100247
GAINESVILLE FL 32610

My name is Padraic O’Malley, MSc, MD, FRCSC, and I am a clinical assistant professor in the University of Florida Department of Urology and chief of urologic oncology. Following medical school at Saba University School of Medicine, I completed my urology residency at the University of Toronto in Toronto, Canada, where I was awarded the Undergraduate Teaching Award. I completed my urologic oncology fellowship at Weill-Cornell Medical College in New York, New York, where I was awarded the Ferdinand C. Valentine Fellowship Award. I joined UF Health in 2018 and have since been awarded a UF College of Medicine Exemplary Teacher award as well as the Department of Urology Rising Star Award.

Currently, I am a board member of the Florida Urological Society and Southeastern section of the American Urological Association. I am also a member of the American Urological Association, the Canadian Urological Association, the Endourological Society and the Society of Urologic Oncology, in addition to being an international member of the European Association of Urology. Along with seeing patients and teaching, I have contributed as an author to a number of urology-based publications, chapters and abstracts.

My clinical interests revolve around urologic oncology, multidisciplinary care and robotic surgical techniques. I perform complex robotic surgery with a special interest in bladder and kidney cancer. This includes treating IVC thrombus, performing robotic and open tumor thrombectomies, and robotic and open retroperitoneal lymph node dissection. I serve as a sub-investigator on a number of clinical trials for bladder, kidney and prostate cancer. My research interests examine the tumor microenvironment in bladder and kidney cancer, the use of novel nanoparticle and artificial intelligence-powered analysis of exosome-based, multi-fluid multi-omics in bladder cancer, and the use of surgery in advanced kidney cancer.

During my free time, I enjoy spending time with my wife and children, traveling, playing and watching sports (rugby, in particular), and cooking with my smoker.

Certifications:
  • Urology
    The American Board of Urology
Specialties:
  • Cancer
  • Urology
Clinical Interests:
  • Adrenocortical Carcinoma
  • Bladder Cancer
  • Kidney Cancer
  • Kidney Removal
  • Laparoendoscopic Single Site (LESS) Surgery
  • Laparoscopic Radical Nephrectomy
  • Laparoscopic and Robotic Nephroureterectomy
  • Laparoscopic and Robotic Partial Nephrectomy
  • Penile Cancer
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Renal Vein Thrombosis
  • Robotic Surgery
  • Robotic and Laparoscopic Urologic Surgery
  • Testicular Cancer
  • UF Health robotic prostatectomy
  • Upper Tract Urothelial Cancer
  • Urologic Cancer
Research Interests:
  • Minimally invasive urological surgical therapies
  • Urologic Oncology
Publications:
Grants:
  • Sep 2025 ACTIVE
    A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
    UROGEN PHARMA LTD · Principal Investigator
  • Jun 2025 ACTIVE
    A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
    CG ONCOLOGY · Principal Investigator
  • Jun 2025 ACTIVE
    GAIN-BCG: Gemcitabine Alternating with INtravesical BCG randomized against BCG alone for patients with recurrent high grade Non-Muscle Invasive Bladder Cancer
    NRG ONCOLOGY FOU · Principal Investigator
  • May 2025 ACTIVE
    A 3-arm randomized controlled trial evaluating the role of 29MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer
    EXACT IMAGING · Principal Investigator
  • Nov 2024 ACTIVE
    Salvage Focal Therapy via High Intensity Focused Ultrasound (HIFU) in Radiorecurrent Localized Prostate Cancer (FocalHIFU) (NCT06402357)
    EDAP TECHNOMED · Faculty
  • Aug 2024 ACTIVE
    a multi- center registry under a protocol entitled uTRACT Registry Jelmyto? (mitomycin) for pyelocalyceal solution (the Drug)
    UROGEN LTD · Principal Investigator
  • May 2024 ACTIVE
    A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer
    SURGE THERAPEUTICS · Principal Investigator
  • Jan 2023 ACTIVE
    A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Na?ve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
    NRG ONCOLOGY FOU · Principal Investigator
  • Sep 2022 ACTIVE
    UF HEALTH CANCER CENTER PILOT PROJECTS GRANTS FUNDED THROUGHTHE FLORIDA CONSORTIUM OF NATIONAL CANCER INSTITUTE CENTER
    UF HEALTH SHANDS HOSPITAL · Project Manager
  • Apr 2022 – Jan 2024
    Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population
    ANGIODYNAMICS · Principal Investigator
  • Apr 2022 – May 2025
    Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population
    ANGIODYNAMICS · Principal Investigator
  • Apr 2022 – May 2025
    A 3-arm randomized controlled trial evaluating the role of 29MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer
    EXACT IMAGING · Principal Investigator
  • Nov 2020 ACTIVE
    Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE trial)
    NRG ONCOLOGY FOU · Principal Investigator
Education:
  • 2014-2016
    Fellowship, Urological Oncology
    Weill Cornell Medical College and New York Presbyterian Hospital
  • 2009-2014
    Residency
    University of Toronto
  • 2005-2009
    Medical School
    Saba University School of Medicine
Li-Ming Su

Li-Ming Su M.D.

Department Chair and Pete and Carolyn Newsome Endowed Chair Of Urologic Oncology
Department: MD-UROLOGY
Mailing Address:
PO Box 100247
GAINESVILLE FL 32610
Physical Address:
1600 SW ARCHER RD
GAINESVILLE FL 32610

My name is Li-Ming Su, MD, and I am the Pete and Carolyn Newsome Professor of Urologic Oncology and Chair of the University of Florida Department of Urology. I completed my residency in urology at the New York Presbyterian Hospital-Weill Cornell Medical College and an advanced fellowship in robotics and laparoscopic surgery at The Johns Hopkins Hospital. Prior to joining UF, I served eight years on faculty at the James Buchanan Brady Urological Institute at Johns Hopkins. As a proud Gainesville native, I am glad to be serving the community I grew up in and am especially proud to lead the No. 1 academic urology program in the state of Florida.

My clinical interests include minimally invasive laparoscopic and robotic surgery for prostate cancer, kidney cancer, adrenal tumors and urothelial cancer of the kidney. My research focus is on exploring advanced imaging as applied to urologic oncologic surgery.

As a physician, my goal is to provide patients with outstanding, compassionate care tailored to their unique circumstance and urologic condition.

Outside of medicine, I enjoy saltwater fishing, playing tennis, raising koi fish and spending time with my wife, son, and two dogs.

Accomplishments:
  • Secretary General
    2021-Current · Endourological Society
  • Certificate of Recognition for education and teaching as well as outstanding professional accomplishments
    2021 · American Urological Association
  • Diploma of Fellowship FRCS(Glasg)
    2020-Current · Royal College of Physicians and Surgeons of Glasgow
  • American Board of Urology Oral Examination Committee
    2020-Current · American Board of Urology
  • American Board of Urology Written Emanation Committee
    2012-2015 · American Board of Urology
  • America’s Top Doctors for Cancer
    2010-2021 · Castle Connolly Medical Ltd
  • Distinguished Customer Service Award
    2009 · UF Health
  • First Prize, Audio-Visual Award: Nerve-sparing during laparoscopic radical prostatectomy: adhering to the high standard of open surgery
    2004 · American Urological Association Meeting
  • First Prize, Ambrose-Reed Socioeconomic Essay Contest: Making ends meet: a cost comparison of laparoscopic and open radical retropubic prostatectomy
    2004 · American Urological Association Meeting
Certifications:
  • Urology
    American Board of Urology
Specialties:
  • Urology
Clinical Interests:
  • Adrenal Gland Removal
  • Adrenocortical Carcinoma
  • Cushing Syndrome Due to Adrenal Tumor
  • Kidney Cancer
  • Laparoscopic Radical Nephrectomy
  • Laparoscopic Renal Cyst Ablation
  • Laparoscopic Robotic Pyeloplasty
  • Laparoscopic and Robotic Nephroureterectomy
  • Laparoscopic and Robotic Partial Nephrectomy
  • Laparoscopy and Robotic Adrenalectomy
  • Pheochromocytoma
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Renal Pelvis or Ureter Cancer
  • Robotic Surgery
  • Robotic and Laparoscopic Urologic Surgery
  • UF Health robotic prostatectomy
  • Upper Tract Urothelial Cancer
  • Urologic Cancer
Research Summary:

Dr. Su’s clinical interests are in minimally invasive surgical therapies for kidney cancer and robotic prostatectomy for prostate cancer.

His research focuses on exploring advanced imaging for prostate and kidney cancer, robotic simulation and  and trialing new minimally invasive biomedical technology.

Specialties: Robotic and laparoscopic surgery for prostate, urothelial and kidney cancer, adrenal tumors, and kidney obstruction (pyeloplasty)

Publications:
Grants:
  • Sep 2025 ACTIVE
    Urology CTOA
    UNIV OF FLORIDA · Principal Investigator
  • Sep 2018 – Aug 2023
    2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity Center
    NATL INST OF HLTH NCI · Other
Education:
  • 2001
    Fellowship – Minimally Invasive Surgery
    Brady Urological Institute – Johns Hopkins Hospital
  • 2000
    Residency – Urology
    New York Presbyterian Hospita l- Cornell
  • 1996
    Residency – Surgery
    New York Presbyterian Hospital – Cornell
  • 1995
    Internship – Surgery
    New York Presbyterian Hospital – Cornell
  • 1994
    Medical Degree
    Weill-Cornell University Medical College

Top of Page